You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Current and future role of biomarkers in Crohn's disease risk assessment and treatment
|
|---|---|
| Published in |
Clinical and Experimental Gastroenterology, June 2011
|
| DOI | 10.2147/ceg.s18187 |
| Pubmed ID | |
| Authors |
Cyrus P Tamboli, David B Doman, Amar Patel |
| Abstract |
Crohn's disease (CD), a chronic inflammatory bowel disease (IBD), occurs in genetically susceptible individuals who develop aberrant immune responses to endoluminal bacteria. Recurrent inflammation increases the risk of several complications. Despite use of a traditional "step-up" therapy with corticosteroids and immunomodulators, most CD patients eventually require surgery at some time in their disease course. Newer biologic agents have been remarkably effective in controlling severe disease. Thus, "top-down," early aggressive therapy has been proposed to yield better outcomes, especially in complicated disease. However, safety and cost issues mandate the need for careful patient selection. Identification of high-risk candidates who may benefit from aggressive therapy is becoming increasingly relevant. Serologic and genetic markers of CD have great potential in this regard. The aim of this review is to highlight the clinical relevance of these markers for diagnostics and prognostication. |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 3% |
| Portugal | 1 | 2% |
| Unknown | 60 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 27% |
| Other | 9 | 14% |
| Student > Ph. D. Student | 8 | 13% |
| Student > Master | 6 | 10% |
| Student > Bachelor | 4 | 6% |
| Other | 14 | 22% |
| Unknown | 5 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 46% |
| Agricultural and Biological Sciences | 12 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Economics, Econometrics and Finance | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 7 | 11% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 January 2013.
All research outputs
#7,566,159
of 23,736,443 outputs
Outputs from Clinical and Experimental Gastroenterology
#109
of 315 outputs
Outputs of similar age
#40,446
of 113,224 outputs
Outputs of similar age from Clinical and Experimental Gastroenterology
#2
of 4 outputs
Altmetric has tracked 23,736,443 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 315 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 113,224 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.